Figure 1/3




5-FormylTHF
MTHFS
5,10-MethenylTHF
MTHFD
5,10-MethyleneTHF
PURINES
DNA SYNTHESIS
dUMP
TS
dTMP
DHF
THF
DHFR
SHMT1
MTHFR
5-MethylTHF
METHYLATION REACTIONS

Figure 2/3

		Doses					
Patient no	Treatment line	[6R]-MTHF mg/m^2	5-FU mg/m^2	Oxaliplatin mg/m^2	Irinotecan mg/m^2	Response rate acc to RECIST 1.1.after 8 weeks	Response rate acc to RECIST 1.1.after 16 weeks
1	1	2 x 30	2 x 500	-	-	0,00	-
2	1	2 x 30	2 x 500	-	-	-13,97	-
3	1	2 x 30	2 x 500	-	-	-27,27	-
4	1	2 x 60	2 x 500	-	-	7,02	-14,04
5	1	2 x 60	2 x 500	-	-	1,92	0,00
6	3	2 x 120	2 x 500	-	-	30,77	-
7	3	2 x 120	2 x 500	-	-	-2,15	-
8	3	2 x 120	2 x 500	-	-	6,03	22,41
9	2	2 x 240	2 x 500	-	-	19,35	38,71
10	1	2 x 240	2 x 500	-	-	-51,22	-51,22
11	2	2 x 240	2 x 500	-	-	-21,43	-
12	2	2 x 30	2 x 500	85	-	-17,98	-
13	2	2 x 30	2 x 500	85	-	-6,85	-6,85
14	2	2 x 30	2 x 500	85	-	-27,27	-
15	2	2 x 60	2 x 500	85	-	-41,86	-18,6*
16	3	2 x 60	2 x 500	85	-	-20,51	-
17	2	2 x 60	2 x 500	85	-	-4,55	-
18	1	2 x 60	2 x 500	85		-40,00	-42,50
19	3	2 x 60	2 x 500	85		-12,70	-
20	3	2 x 30	2 x 500	85		26,00	-
21	1	2 x 30	2 x 500	-	180	-41,86	-
22	2	2 x 30	2 x 500	-	180	14,30	-
23	1	2 x 30	2 x 500	-	180	0,00	3,18
24	5	2 x 30	2 x 500	-	180	-6,56	-
25	3	2 x 60	2 x 500	-	180	18,07	-
26	2	2 x 60	2 x 500	-	180	60,38	-
27	1	2 x 60	2 x 500	-	180	-88,33	-86,67
28	1	1 x 60 [1)]	1 x 400 2400 [2)]	85	-	-31,58	-31,58
29	1	1 x 60 [1)]	1 x 400 2400 [2)]	85	-	-38,46	-60,44
30	2	1 x 60 [1)]	1 x 400 2400 [2)]	85	-	-44,74	-56,14
31	2	1 x 120 [3)]	1 x 400 2400 [2)]	85	-	*)	-
32	2	1 x 120 [3)]	1 x 400 2400 [2)]	85	-	13.95	-
33	2	1 x 120 [3)]	1 x 400 2400 [2)]	85	-	*)	-
35	2	1 x 120 [3)]	1 x 400 2400 [2)]	85	-	*)	-
36	2	1 x 120 [3)]	1 x 400 2400 [2)]	85	-	-1,14	-
37	2	1 x 120 [3)]	1 x 400 2400 [2)]	85	-	0,00	-
38	2	1 x 120 [3)]	1 x 400 2400 [2)]	85	-	-8,57	-

Note: [1)] Divided into 2 separate bolus doses of 30 mg on Day 1, [2)] 46 hours infusion
[3)] divided into 2 separate bolus doses of 60 mg on Day 1, [4)] + bevacizumab (5mg/kg)
[*)] the appearance of one or more lesions is considered Progressive Disease

Figure 3/3



	CoFactor/ 5-FU (n= 147)	Leucovorin /5-FU (n= 148)	P-value
Patients reporting at least 1 hematological or gastrointestinal adverse event of grade 3 or greater	23	10	p< 0.05
Hematological	11	7	
Gastrointestinal	12	5	

ADVENTRX PHARMACEUTICALS

	CoFactor/5-FU (n= 150)	Leucovorin /5-FU (n= 150)
Objective response rate	10.7%	13.3%
Median Progression-free Survival (months)	6.3mo	6.1mo
Preliminary Median Survival (months)	14.7mo	14.3mo